Bevacizumab plus trastuzumab plus chemotherapy for primary inflammatory HER2-positive BC was evaluated in a Phase II, open-label, single-arm trial (BEVERLY-2) in 52 patients from 21 centers (Pierga et al. 2012). This evidence concerns the gene ERBB2 and breast cancer.